Altimmune, Inc. (ALT)

NGM – Цена в реальном времени. Валюта: USD

3.08

-0.01 (-0.32%)

При закрытии: May 12, 2026, 4:00 PM EDT

3.14

+0.06 (1.94%)

До открытия: May 13, 2026, 5:27 AM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Altimmune, Inc. (ALT)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Altimmune, Inc. (ALT)

Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026

Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities

Altimmune Catalysts: 2026 Data Readouts and Financing Risks

ALT Stock: What Pemvidutide Means for MASH, AUD and ALD

Is Altimmune a Buy Before Phase III MASH Starts in 2026?

Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities

Altimmune Announces Proposed Underwritten Public Offering of Securities

Видео

No Data

Пресс-релизы

Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities

Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities

Altimmune Announces Proposed Underwritten Public Offering of Securities

Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates

Search stocks

Altimmune, Inc. (ALT)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Altimmune, Inc. (ALT)

Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026

Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities

Altimmune Catalysts: 2026 Data Readouts and Financing Risks

ALT Stock: What Pemvidutide Means for MASH, AUD and ALD

Is Altimmune a Buy Before Phase III MASH Starts in 2026?

Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities

Altimmune Announces Proposed Underwritten Public Offering of Securities

Видео

No Data

Пресс-релизы

Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities

Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities

Altimmune Announces Proposed Underwritten Public Offering of Securities

Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates